药学学报, 2018, 53(4): 509-517
引用本文:
李孝贤, 刘仁帅, 方浩. Bcl-2:从靶标到上市药物的研究进展[J]. 药学学报, 2018, 53(4): 509-517.
LI Xiao-xian, LIU Ren-shuai, FANG Hao. Bcl-2: research progress from target to launched drug[J]. Acta Pharmaceutica Sinica, 2018, 53(4): 509-517.

Bcl-2:从靶标到上市药物的研究进展
李孝贤, 刘仁帅, 方浩
山东大学药学院药物化学研究所, 山东 济南 250012
摘要:
细胞凋亡对正常生命体的发育、维持内环境的稳态具有重要作用,而该过程的异常常常会引发机体病变。研究表明Bcl-2蛋白家族与细胞凋亡过程密切相关,而且也是治疗肿瘤的重要靶标。经过近20年的努力,已经发现了许多小分子Bcl-2抑制剂。特别是基于片段药物设计策略发现的小分子Bcl-2抑制剂venetoclax已于2016年被美国FDA批准上市。作为首个获批的基于蛋白-蛋白相互作用为靶点的小分子药物,venetoclax的研发综合运用了多种药物研发技术,在新药研发的历史中具有里程碑式的意义。本文主要对临床研究的Bcl-2抑制剂的研发历程进行简述。
关键词:    细胞凋亡      Bcl-2抑制剂      蛋白-蛋白相互作用     
Bcl-2: research progress from target to launched drug
LI Xiao-xian, LIU Ren-shuai, FANG Hao
Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jinan 250012, China
Abstract:
Apoptosis is an important self-stabilizing mechanism of multicellular organisms, which plays a vital role in the development of normal living organisms and the maintenance of tissue homeostasis. The abnormalities in apoptosis often lead to body lesions including tumors. Studies have shown that Bcl-2 protein with anti-apoptosis activity is an important target in the treatment of cancer. After nearly two decades of efforts, many small molecule Bcl-2 inhibitors have been discovered to induce cell apoptosis. The small-molecule Bcl-2 inhibitor, venetoclax, was developed based on fragment-based drug design strategy and approved by the FDA in 2016 for clinical application. This agent is the first approved small-molecule drug inhibiting Bcl-2 through protein-protein interaction to induce cell apoptosis. The achievement of venetoclax benefits from a combination of drug discovery technologies and represents a milestone in the history of drug discovery. In this review we will introduce the current progress in Bcl-2 inhibitors.
Key words:    apoptosis    Bcl-2 inhibitor    protein-protein interaction   
收稿日期: 2017-12-05
DOI: 10.16438/j.0513-4870.2017-1210
基金项目: 国家自然科学基金资助项目(21672127).
通讯作者: 方浩,Tel:86-531-88382019,E-mail:haofangcn@sdu.edu.cn
Email: haofangcn@sdu.edu.cn
相关功能
PDF(447KB) Free
打印本文
0
作者相关文章
李孝贤  在本刊中的所有文章
刘仁帅  在本刊中的所有文章
方浩  在本刊中的所有文章

参考文献:
[1] Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer:a review of apoptosis, autophagy and programmed necrosis[J]. Cell Prolif, 2012, 45:487-498.
[2] Kerr JF, Wyllie AH, Currie AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics[J]. Br J Cancer, 1972, 26, 239-257.
[3] Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation[J]. Science, 1984, 226:1097-1099.
[4] Zhang X, Chen Y, Jenkins LW, et al. Bench-to-bedside review:apoptosis/programmed cell death triggered by traumatic brain injury[J]. Crit Care, 2005, 9:66-75.
[5] Cory S, Huang DCS, Adams JM. The Bcl-2 family:roles in cell survival and oncogenesis[J]. Oncogene, 2003, 22:8590-8607.
[6] Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death[J]. J Clin Investig, 2005, 115:2648-2655.
[7] Adams JM, Cory S. Bcl-2-regulated apoptosis:mechanism and therapeutic potential[J]. Curr Opin Immunol, 2007, 19:488-496.
[8] Agrawal S, Zhao Q. Antisense therapeutics[J]. Curr Opin Chem Biol, 1998, 2:519-528.
[9] Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-then and now[J]. Am J Hematol, 2016, 91:330-340.
[10] Vitale C, Burger JA. Chronic lymphocytic leukemia therapy:new targeted therapies on the way[J]. Expert Opin Pharmacother, 2016, 17:1077-1089.
[11] O'Brien SM, Cunningham CC, Golenkov AK, et al. Phase I to Ⅱ multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia[J]. J Clin Oncol, 2005, 23:7697-7702.
[12] O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase Ⅲ trial of fludarabine plus cyclophosphamide with or without oblimersen[J]. J Clin Oncol, 2009, 27:5208-5212.
[13] Wang JL, Zhang ZJ, Choksi S, et al. Cell permeable Bcl-2 binding peptides:a chemical approach to apoptosis induction in tumor cells[J]. Cancer Res, 2000, 60:1498-1502.
[14] Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells[J]. Proc Natl Acad Sci USA, 2000, 97:7124-7129.
[15] Tian D, Das SG, Doshi JM, et al. sHA14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell[J]. Cancer Lett, 2008, 259:198-208.
[16] Kitada S, Leone M, Sareth S, et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins[J]. J Med Chem, 2003, 46:4259-4264.
[17] James DF, Castro JE, Loria O, et al. AT-101, a small mole-cule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; preliminary results from an ongoing phase I trial[J]. J Clin Oncol, 2006, 24:6605.
[18] Castro JE, Loria OJ, Aguillon RA. A phase Ⅱ, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens[J]. Blood, 2007, 110:3119.
[19] Becattini B, Kitada S, Leone M, et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-xL[J]. Chem Biol, 2004, 11:389-395.
[20] Wang G, Nikolovska-coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins[J]. J Med Chem, 2006, 49:6139-6142.
[21] Wolter KG, Wang SJ, Henson BS, et al. (-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo[J]. Neoplasia, 2006, 8:163-172.
[22] Mohammad RM, Goustin AS, Aboukameel A, et al. Pre-clinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1[J]. Clin Cancer Res, 2007, 13:2226-2235.
[23] Joudeh J, Claxton D. Obatoclax mesylate:pharmacology and potential for therapy of hematological neoplasms[J]. Expert Opin Investig Drugs, 2012, 21:363-373.
[24] Wang L, Sloper DT, Addo SN, et al. WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth[J]. Cancer Res, 2008, 68:4377-4383.
[25] Yap JL, Chen L, Lanning ME, et al. Expanding the cancer arsenal with targeted therapies:disarmament of the anti-apoptotic Bcl-2 proteins by small-molecules[J]. J Med Chem, 2017, 60:821-838.
[26] Shuker SB, Hajduk PJ, Meadows RP, et al. Discovering high-affinity ligands for proteins:SAR by NMR[J]. Science, 1996, 274:1531-1534.
[27] Guo ZR. Venetoclaxt——the first inhibitors of protein-protein interaction[J]. Acta Pharm Sin (药学学报), 2018, 53:476-486.
[28] Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours[J]. Nature, 2005, 435:677-681.
[29] Tse C, Shoemaker AR, Adickes J, et al. ABT-263:a potent and orally bioavailable Bcl-2 family inhibitor[J]. Cancer Res, 2008, 68:3421-3428.
[30] Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival[J]. Cell Death Differ, 2007, 14:943-951.
[31] Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets[J]. Nat Med, 2013, 19:202-208.
[32] Green DR. A BH3 mimetic for killing cancer cells[J]. Cell, 2016, 165:1560.
[33] Roberts AW, Davids MS, Pagel JM, et al. Targeting bcl-2 with venetoclax in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2016, 374:311-322.
[34] Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion:a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2016, 17:768.
[35] Jones JA, Wierda WG, Choi MY, et al. Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib[abstract no. 7519] [C]. Chicago:ASCO Annual Meeting, 2016.